Evidence map›Paper›PMID 41413343›Full record

ArticleNature communications2025

Molecular mechanisms of receptor recognition and antibody neutralization of coxsackievirus A6.

Xianliang Ke, Xue Li, Zeyu Liu, Kexin Liu, Weichi Liu, Xingyu Yan, Bo Shu, Chao Zhang

Erratum issuedAbstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Serial passagingFrontiers in cellular and infection microbiology · 2026
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Xianliang Ke *State Key Laboratory of Virology and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, Hubei, China.
Xue Li *Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai, China.
Zeyu Liu *Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai, China.
Kexin LiuShanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai, China.
Weichi LiuState Key Laboratory of Virology and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, Hubei, China.
Xingyu YanShanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai, China.
Bo ShuState Key Laboratory of Virology and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, Hubei, China. shubo@wh.iov.cn.
Chao ZhangShanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai, China. chao_zhang@fudan.edu.cn.ORCID http://orcid.org/0000-0002-8658-9009

Funding

National Natural Science Foundation of China (National Science Foundation of China) 82472252
6 · The paper itself

Abstract

Coxsackievirus A6 (CVA6), a major cause of hand, foot, and mouth disease, lacks approved vaccines or drugs. KRM1 is its only known receptor, but its precise role remains unclear. This study investigates CVA6's entry mechanism and antibody neutralization. Cryo-EM shows CVA6 clinical strain HeB primarily exists as mature virions. KRM1 binding within the canyon triggers conversion to uncoating intermediate, defining KRM1 as an uncoating receptor for CVA6. However, KRM1 knockout reduces CVA6 infectivity without affecting attachment. Conversely, disrupting heparan sulfate proteoglycan (HSPG) impairs both viral attachment and infectivity, and CVA6 virions bind heparin directly. These results support a two-receptor entry model for CVA6: HSPG mediates viral attachment, while KRM1 induces uncoating. Additionally, we develop two CVA6-specific protective antibodies (1F4 and 3H7), targeting a new antigenic site near the three-fold axis of the viral capsid. These antibodies sterically block KRM1 binding and function post-attachment, consistent with KRM1's role. The findings elucidate CVA6 entry and offer a basis for antibody interventions.

Indexed as

Antibodies, NeutralizingAntibodies, ViralEnterovirusEnterovirus A, HumanReceptors, VirusAnimalsCapsidCapsid ProteinsCryoelectron MicroscopyHeparan Sulfate ProteoglycansHumansMiceNeutralization TestsProtein BindingVirionVirus AttachmentAntibodies, NeutralizingAntibodies, ViralCapsid ProteinsHeparan Sulfate ProteoglycansReceptors, Virus

Identifiers

PMID41413343
PMCPMC12830800

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.